Blonder Tongue Laboratories, In
0.0300+0.01 (+50%)
Oct 29, 4:00:00 PM EDT · OTC Markets OTCPK · BDRL · USD
Key Stats
Market Cap
434.16KP/E (TTM)
-Basic EPS (TTM)
-0.09Dividend Yield
0%Recent Filings
10-K
FY2022 results
Blonder Tongue Laboratories' 10-K filing for the fiscal year ended December 31, 2022, lacks financial statements, MD&A details, or quarterly breakdowns, preventing analysis of revenue, profitability, or Q4 momentum. Without primary figures or drivers, annual context remains unclear, and no y/y deltas or segment performance can be assessed. Liquidity and capital allocation trends are not disclosed. No guidance for 2023 appears in the provided text. Supply chain disruptions, flagged in Risk Factors, could hinder quarterly recovery efforts.
8-K
Interim CFO appointed after death
Blonder Tongue Laboratories announced the sudden death of its Senior Vice President and Chief Financial Officer Eric Skolnik on February 23, 2023, prompting the board to appoint long-time Controller Michael Censoplano as Interim CFO effective immediately. Censoplano, with the company for over 22 years, will earn an annual salary of $111,728.24 and access standard benefits. This leadership shift ensures financial continuity amid the loss of a key executive who served for two decades. More details on permanent arrangements are pending.
8-K
Director retires post-annual meeting
Blonder Tongue Laboratories director Stephen K. Necessary announced his retirement from the board effective immediately after the May 24, 2023 annual stockholder meeting. Having served since 2018, his departure stems from personal choice, not any discord with management or the board. This smooth transition preserves continuity amid ongoing operations.
8-K
CEO resigns; Palle reappointed
Blonder Tongue Laboratories announced CEO Edward Grauch's resignation effective March 18, 2023, after leading since 2020 amid pandemic and supply chain hurdles. The board reappointed veteran Robert J. Palle as CEO and President starting that date, leveraging his 30+ years in cable tech and prior roles at the firm. Palle's $156,000 salary underscores continuity. Yet, leadership shakeup signals transition risks.
8-K
CEO defers pay extension
Blonder Tongue Laboratories extended CEO Edward R. Grauch's deferred compensation through June 3, 2023, suspending all cash pay starting January 1 while accruing it for later settlement in cash, stock, or both by June 30—at the board's discretion. This builds on a prior 180-day deferral from May 2022, aligning executive incentives with company liquidity. In a change of control, accrued pay becomes immediately due in cash. Yet the firm preserves cash amid challenges.
IPO
Employees
Sector
Industry
BDC
Belden Inc
119.37+1.60
BKTI
BK Technologies Corporation
73.47+0.97
CMTL
Comtech Telecommunications Corp
2.93-0.20
DLB
Dolby Laboratories
64.95-1.60
GILT
Gilat Satellite Networks Ltd.
14.45-0.26
HLIT
Harmonic Inc.
10.38-0.17
SYNX
Silynxcom Ltd.
1.64-0.01
TSAT
Telesat Corporation
30.49-0.68
VISL
Vislink Technologies, Inc.
2.47-0.11
VSAT
ViaSat, Inc.
39.17-0.24